Last reviewed · How we verify

NCT00005608

Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer

Terminated Phase 2 Last updated 31 May 2012
What this trial tests

Phase 2 trial testing leucovorin calcium in Breast Cancer. Terminated before completion.

Timeline
1 February 2000
Primary endpoint
1 June 2002
1 June 2002

Quick facts

Lead sponsorNorthwestern University
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Primary purposetreatment
Start date1 February 2000
Primary completion1 June 2002
Estimated completion1 June 2002
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwestern University

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of fluorouracil-uracil and leucovorin in treating women who have metastatic breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of leucovorin calcium

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Northwestern University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00005608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing